KRAMER, JOEL H
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
USA
Novel imaging and endothelial biomarkers of small vessel cerebrovascular disease
NIH (NIA)
2,858,903.67
30/09/2016
2
Alzheimer's disease & other dementias
Cerebrovascular Disorders, Microvascular Dysfunction, Serological, endothelial dysfunction, CXCL6 gene
Project Summary /Abstract Small vessel cerebrovascular disease and Alzheimer’s disease are the two most common causes of cognitive decline in the elderly, but methods for determining the relative contributions of both these pathologies to functional impairment, understanding their interactions, predicting progression and defining targets for clinical trials remain underdeveloped. The overarching goal of this proposal is to further develop novel neuroimaging and serologic biomarkers of cerebrovascular disease. Accomplishing this goal will improve early detection, diagnosis, and prognosis of small vessel cerebrovascular disease in older subjects, and provide better targets and outcome metrics for clinical trials. We propose to longitudinally study 400 well characterized older subjects from ongoing projects at UCSF and UCD who present with a range of cerebrovascular burden and functional decline. Our search for biomarkers will focus on novel neuroimaging variables and measures of endothelial dysfunction. Our aims will address the relationships between these markers and measures of amyloid burden, cognition, and change over time.
Project Narrative Small vessel cerebrovascular disease and Alzheimer’s disease are the two most common causes of cognitive decline in the elderly, but methods for determining the relative contributions of both these pathologies to functional impairment, understanding their interactions, predicting progression and defining targets for clinical trials remain underdeveloped. The overarching goal of this proposal is to further develop novel neuroimaging and serologic biomarkers of cerebrovascular disease. Accomplishing this goal will improve early detection, diagnosis, and prognosis of small vessel cerebrovascular disease in older subjects, and provide better targets and outcome metrics for clinical trials.